CTS2190 Phase I /II Clinical Study in Patients

Recruitment & Eligibility

Status: Recruiting

Sex: All

Target Recruitment: 224

Inclusion Criteria

Inclusion Criteria: Subjects who meet all of the following criteria can be included in this study: 1. Male or female = 18 years of age at signing of ICF. 2. Part 1: histologically or cytologically confirmed locally advanced or metastatic solid tumors at screening who cannot be treated surgically and have failed standard treatment (PD during treatment or after the last treatment) recommended by the current clinical diagnosis and treatment standards or guidelines, or cannot tolerate standard treatment, or refuse standard treatment and/or currently have no effective treatment available. Part 2: histologically or cytologically confirmed advanced solid tumors (including pancreatic cancer, non-small cell lung cancer and/or other tumors, such as gastric cancer, colorectal cancer, etc.) at screening who cannot be treated surgically and have failed standard treatment (PD during treatment or after the last treatment) recommended by the current clinical diagnosis and treatment standards or guidelines, or cannot tolerate standard treatment, or refuse standard treatment and/or currently have no effective standard treatment available. 3. At least one measurable tumor lesion at screening [according to RECIST V1.1 criteria (see appendix 1)]. 4. Eastern Cooperative Oncology Group (ECOG) performance status of = 1 (Appendix 2) at screening. 5. With a life expectancy = 12 weeks at screening. 6. With good organ function at screening, including: - Liver function: total bilirubin (TBIL) = 1.5 × upper limit of normal (ULN) (if the following conditions occur, isolated bilirubin >1.5 × ULN is acceptable if: bilirubin is fractionated and direct bilirubin <35%, or the patients is diagnosed with Gilbert syndrome), alanine aminotransferase (ALT) = 2.5 × ULN, and aspartate aminotransferase (AST) = 2.5 × ULN (for patients with liver metastases or tumor infiltration, the criteria can be relaxed to TBIL = 1.5 × ULN, ALT =5 × ULN, and AST = 5 × ULN); - Renal function: blood creatinine = 1.5 × ULN and creatinine clearance = 50 mL/min [calculate the creatinine clearance using Cockcroft-Gault formula (appendix 3)]; - Hematology: platelet = the lower limit of the laboratory normal range, and absolute neutrophil count (ANC) = 1.5 × 109/L, and hemoglobin = 100 g/dL; - Cardiac function: QT interval corrected by Fridericia method (QTcF) = 450 ms (male) or = 470 ms (female) (see the appendix 3 for calculation formula). - Coagulation function: International normalized ratio (INR) = 1.5 × ULN, or activated partial thromboplastin time (APTT) = 1.5 × ULN. 7. Female patients of non-childbearing age or female patients of childbearing age who have negative pregnancy test results and promise to take sufficient and effective contraceptive measures or adhere to abstinence from the screening period to 90 days after the last administration, or male patients who promise to take sufficient and effective contraceptive measures or adhere to abstinence from the screening period to 90 days after the last administration (see the appendix 4). Patients are not allowed to donate sperm within 6 months from the start of administration to 6 months after the end of investigational drug administration. 8. Patients who understand and voluntarily signs the ICF, are willing to and able to complete the scheduled visits, treatment plan, laboratory tests and other study procedures. Exclusion Criteria: Subjects should not participate in this clinical study if any of the following conditions is met: 1. Female patients in pregnancy or lactation. 2. Patients with dysphagia. 3. Patients who cannot tolerate venipuncture or have a history of syncope judged by the investigator to be clinically significant. 4. Uncontrolled tumor-related pain. 5. Allergic or intolerant to the active ingredients or excipients of the investigational drug judged by the investigator. 6. Treatment with radiotherapy for the target lesion within 4 weeks before the first administration of the investigational drug, or accepted any anti-tumor drugs/ treatments (including but not limited to chemotherapy, targeted therapy, immunotherapy) within 5 half-lives before the first administration of the investigational drug, whichever is longer; or patients who have received herbal therapies with anti-tumor indications within 1 week before the first administration. 7. Primary central nervous system (CNS) tumor or CNS metastasis at screening. The following patients can be considered for enrollment: after treatment and being stable for = 3 months, patients who have completed the treatment at least 10 days before the start of the study treatment; the corticosteroid treatment has been terminated for = 5 days when the study treatment starts, the neurological function is stable, and it is estimated that no steroids or antiepileptic drugs will be required during the study treatment. 8. Patients judged by the investigator to have uncontrolled pleural effusion, pericardial effusion, or peritoneal effusion (requiring repeated drainage, multiple times a month or more frequently) at screening. Allow patients to indwell catheters regardless of drainage frequency. 9. Patients with untreated or clinically symptomatic spinal cord compression that has not been controlled (except for patients who have received treatment and have stable symptoms, whose imaging examination shows that they are stable for at least 4 weeks before the first administration, and who have no evidence of brain edema and do not require glucocorticoid treatment). 10. Patients with = 2 malignant tumors within 5 years before the first administration. Except for cured early-stage malignancies (carcinoma in situ or stage I tumor), such as adequately treated cervical carcinoma in situ, basal cell or squamous epithelial cell skin cancer. 11. Patients who are found to have active pulmonary tuberculosis infection within 1 year before enrollment through medical history, or those with a history of active pulmonary tuberculosis infection more than one year ago who have not received formal treatment. 12. Interstitial lung disease or interstitial pneumonia, including clinically significant radiation pneumonia (i.e., affecting activities of daily living or requiring intervention). 13. Severe infection within 4 weeks before the first administration, including but not limited to bacteremia and severe pneumonia, etc. requiring hospitalization; CTCAE = grade 2 active infection requiring systemic antibiotic treatment within 2 weeks before the first administration. 14. History of serious cardiovascular and cerebrovascular diseases, including but not limited to serious cardiac rhythm or conduction abnormalities, such as ventricular arrhythmia requiring clinical intervention, degree II-III atrioventricular block, etc.; acute coronary syndrome, congestive cardiac failure, aortic dissection, stroke or other grade 3 or above cardiovascular and cerebrovascular events within 6 months before the first administration; New

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Dose Escalation:The maximum tolerated dose (MTD);Dose Escalation:The recommended phase 2 dose (RP2D);Dose Expansion:Objective response rate(ORR)

Secondary Outcome Measures

Name	Time	Method

Related Trials

A study of the safety, pharmacokinetics, and therapeutic activity of cibisatamab in combination with atezolizumab in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors

CompletedPhase 1

Genentech, Inc

Updated 7/5/2021

The first clinical trial to assess safety and efficacy of ONO-7579 in the patients with solid cancers (with or without a specific genetic marker - NTRK gene fusion)

Phase 1

Ono Pharmaceutical Co., Ltd.

Updated 12/10/2019

An open-label, multicenter, dose escalation and expansion Phase Ib study to evaluate the safety, pharmacokinetics and therapeutic activity of RO6958688 in combination with atezolizumab in patients with locally advanced and/or metastatic CEA-positive solid tumors

Completed

Roche Nederland B.V.

Updated 4/23/2024

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

CB BIOSCIENCES, Inc.

Updated 7/10/2015

Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NH

RecruitingPhase 1

Suzuki Kazuyuki

Updated 10/17/2023

A study of the experimental drug KW-2478 in combination with Bortezomib in patients with multiple myeloma.

Phase 1

Kyowa Hakko Kirin Pharma, Inc.

Updated 11/25/2019

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.

F.Hoffmann-La Roche

Updated 5/27/2013

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.

Phase 1

F.Hoffmann-La Roche

Updated 8/21/2017

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease. - ND

F. Hoffmann - La Roche

Updated 9/30/2013

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.

F.Hoffmann-La Roche

Updated 6/3/2013

CTS2190 Phase I /II Clinical Study in Patients

Recruitment & Eligibility

Study & Design

Related Trials

A study of the safety, pharmacokinetics, and therapeutic activity of cibisatamab in combination with atezolizumab in participants with locally advanced and/or metastatic carcinoembryonic antigen (CEA)-positive solid tumors

The first clinical trial to assess safety and efficacy of ONO-7579 in the patients with solid cancers (with or without a specific genetic marker - NTRK gene fusion)

An open-label, multicenter, dose escalation and expansion Phase Ib study to evaluate the safety, pharmacokinetics and therapeutic activity of RO6958688 in combination with atezolizumab in patients with locally advanced and/or metastatic CEA-positive solid tumors

Dose Escalating Study of Rotigotine in Pediatric Subjects With Restless Legs Syndrome

Study of safety and preliminary efficacy of VAY736 given alone or in combination with other antineoplastic agents in patients with NH

A study of the experimental drug KW-2478 in combination with Bortezomib in patients with multiple myeloma.

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease. - ND

An open-label, multi-centre, dose escalating, phase I/randomized phase II study to investigate the safety and tolerability of RO5072759 given as monotherapy in patients with CD20+ malignant disease.

Clinical Trial Alerts

Clinical Trial Alerts